Searchable abstracts of presentations at key conferences in endocrinology

ea0040l17 | Truncated sst5 receptor variants in pituitary tumors and cancer | ESEBEC2016

Truncated sst5 receptor variants in pituitary tumors and cancer

Luque Raul M , Ibanez-Costa Alejandro , Gahete Manuel D , Castano Justo P

Endocrine-related cancers comprise a complex group of heterogeneous pathologies whose development and progression are profoundly conditioned by endocrine–metabolic deregulations. The well-known capacity of somatostatin (SST) to inhibit hormone secretion and cell proliferation in a wide variety of cell types, coupled to the ubiquitous expression of SST receptors (ssts) in normal and tumoral tissues, has led SST analogs (SSAs) to be extensively used in clinical practice for...

ea0040p24 | (1) | ESEBEC2016

Functional role of somatostatin receptor subtype 1 (sst1) in prostate cancer: an in vitro approach

Pedraza-Arevalo Sergio , Hormaechea-Agulla Daniel , Selth Luke A , Castano Justo P , Luque Raul M

Prostate cancer (PC), the most commonly diagnosed malignancy among men, is a complex and heterogeneous disease that is highly influenced by the endocrine environment, which makes difficult the identification of novel therapeutic biomarkers to treat this pathology. Somatostatin (SST) is a pleiotropic neuropeptide that exerts its multiple biological functions, including tumor cell regulation, through a family of receptors (named sst1-5). Particularly, in this study we have found...

ea0040p25 | (1) | ESEBEC2016

Metformin suppressed the proliferation of prostate cancer cells in vitro and reduced prostate tumor growth in vivo under low-fat and, especially, under high-fat fed conditions

Sarmento-Cabral Andre , Lopez-Lopez Fernando , Castano Justo P , Luque Raul M

Obesity (Ob) is a chronic endocrine-metabolic disease and one of the most serious and complex threats for the human health, which is associated with an increased incidence of some types of cancers such as prostate cancer (PC), the second most common cancer in men worldwide. Interestingly, metformin (Met), an antidiabetic drug, might represents a very promising opportunity to treat Ob and PC as some retrospective clinical studies have shown that the incidence of PC is lower in ...

ea0032s11.1 | New mechanisms in SST analogue response | ECE2013

Functional relevance of truncated SST5 receptor variants

Luque Raul M , Ibanez-Costa Alejandro , Gahete Manuel D , Castano Justo P

Somatostatin (SST) and its related peptide cortistatin (CORT) exert multiple physiological actions through binding to a family of G-protein coupled receptors (sst1–sst5), commonly bearing seven transmembrane domains (TMDs). However, we have recently discovered that human, pig and rodent sst5 gene also generate, through non-canonical alternative splicing, novel truncated albeit functional sst5 variants that lack one o more TMDs. Our studies indicate that truncated sst5 var...

ea0032p831 | Pituitary–Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Chracterizazion of somatostatin receptor expression in MENX-assoxciated pituitary adenomas: impact on therapy and imaging with somatostatin analogs

Lee Misu , Lupp Amelie , Gartner Florian , Castano Justo P , Schulz Stephan , Pellegata Natalia

Introduction: Somatostatin analogs (SSAs) are the first-line clinical treatment for patients with pituitary adenomas (PAs) but their efficacy is highly variable among patients. This could be due to a differential expression of somatostatin receptor subtypes (Ssts) among tumors, but this issue is still unresolved. Nonfunctioning pituitary adenomas (NFPAs), which mostly derive from gonadotroph cells, are among the tumors that poorly respond to SSAs. Rats carrying a germline loss...

ea0020oc4.3 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

Homologous and heterologous in vitro regulation of pituitary receptors for somatostatin (SST), growth hormone (GH)-releasing hormone (GHRH) and ghrelin in a non-human primate (Papio anubis)

Chacon Jose Cordoba , Castano Justo P , Kineman Rhonda D , Luque Raul M

Secretion of GH by pituitary somatotropes is primarily stimulated by GHRH and ghrelin and inhibited by SST through the activation of specific receptors (GHRH-R, GHS-R and Sstr1-5, respectively). However, we have previously shown that SST, at low doses, can also stimulate GH release, directly and specifically, in primary pituitary cell cultures from baboons (Papio anubis) and pigs. To determine whether these primary regulators of GH release can also regulate directly the...

ea0022p435 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Molecular analysis of tumor tissue enabled selection of a successful combined therapy of somatostatin and dopamine agonists in a case of TSH-secreting pituitary adenoma

Quintero Ana , Galvez-Moreno M Angeles , Jimenez-Reina Luis , Martinez-Fuentes Antonio J , Benito-Lopez Pedro , Castano Justo P

TSH-secreting pituitary adenomas (thyrotropinomas or TSH-omas) are rare. At diagnosis, TSH-omas are frequently macroadenomas presenting with variable symptoms, and signs of hyperthyroidism. Somatostatin analogs (SSA) are a very efficient treatment to improve clinical signs in patients with TSH-omas, reducing hormone levels (90%) and causing tumor shrinkage (50%).Inhibitory effects of SSA are mediated by a family of five somatostatin receptor subtypes (sst1-5), with sst2 and ss...

ea0022p655 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Kisspeptin selectively increases LH and GH, but not FSH, ACTH, PRL or TSH, release in primary pituitary cell cultures from a non-human primate (Papio anubis) via distinct signaling pathways and under influence of sex steroids

Cordoba-Chacon Jose , Luque Raul M , Gahete Manuel D , Kineman Rhonda D , Tena-Sempere Manuel , Castano Justo P

Kisspeptins (Kp), a peptide family encoded by Kiss1 gene, and their receptor Kiss1r were first identified by their anti-metastatic actions but have emerged as key regulators of the reproductive axis, where they integrate sexual, metabolic and seasonal cues to control hypothalamic GnRH release. Recent data indicates that some actions of Kps may be effected directly at the pituitary (PIT), since Kissr1 is expressed in the PIT and Kp stimulate luteinizing hormone (LH) secretion d...

ea0090p657 | Endocrine-related Cancer | ECE2023

Novel insights to study the potential of the somatostatin system in NETs and NECs

Mangili Federica , Trinidad Moreno Montilla Maria , Garcia Vioque Victor , Pedraza-Arevalo Sergio , Blazquez Encinas Rey Ricardo , Mantovani Giovanna , Peverelli Erika , Schrader Joerg , Ibanez Costa Alejandro , Castano Justo P.

Neuroendocrine tumors (NETs) and carcinomas (NECs) are a heterogeneous group of malignances whose incidence is increasing worldwide. First-line approach is represented by surgery, whereas an effective pharmacological treatment for disseminated and relapsing disease is still needed. Somatostatin (SS) receptors (SSTs) constitute the main suitable pharmacological targets for NETs therapy with SS analogs (SSAs). Nevertheless, a large proportion of NETs and most NECs, are unrespons...

ea0063p266 | Pituitary and Neuroendocrinology 1 | ECE2019

Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH and GH-secreting pituitary adenoma cell lines

Fanciulli Alessandro , Gesmundo Iacopo , Gamba Giacomo , Castano Justo P , Luque Raul M , Alvarez Clara V , Dieguez Carlos , Chiara Zatelli Maria , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETs can be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH) PitNETs. Surgical resection is the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are p...